A61K 39/0258
Escherichia
Official title: {Escherichia}
A61K39/0258 (Escherichia) appears on 447 US grants and 591 published applications in this corpus.
Search patents in A61K- Granted patents
- 447
- Published applications
- 591
- Assignees
- 326
- Inventors
- 1,043
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 5 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 5 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 7 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 1 |
| 2002 | 4 | 11 |
| 2003 | 6 | 13 |
| 2004 | 2 | 12 |
| 2005 | 8 | 14 |
| 2006 | 5 | 14 |
| 2007 | 8 | 14 |
| 2008 | 4 | 14 |
| 2009 | 6 | 15 |
| 2010 | 7 | 23 |
| 2011 | 8 | 28 |
| 2012 | 15 | 19 |
| 2013 | 13 | 19 |
| 2014 | 19 | 19 |
| 2015 | 30 | 39 |
| 2016 | 23 | 51 |
| 2017 | 26 | 32 |
| 2018 | 27 | 23 |
| 2019 | 23 | 26 |
| 2020 | 32 | 28 |
| 2021 | 25 | 32 |
| 2022 | 23 | 30 |
| 2023 | 23 | 26 |
| 2024 | 21 | 39 |
| 2025 | 26 | 30 |
| 2026 | 6 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Composition for delivery of a bioactive agent and method of manufacture and use thereof5 May 2026US 12,616,754 B2National Cheng Kung University
- Immunostimulatory bacteria for the treatment of cancer28 Apr 2026US 12,611,432 B2Northwestern University
- Method for the production of outer membrane vesicles and immunogenic compositions thereof17 Feb 2026US 12,551,544 B2Biomvis Srl
- Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens20 Jan 2026US 12,527,853 B2Vestlandets Innovasjonsselskap AS (VIS)
- Polynucleotide compositions and uses thereof3 Sep 2026US 2026/0256900 A1Pfizer Inc.
- Use of O-Antigens for Treating Bacterial Infections20 Aug 2026US 2026/0240973 A1Agency for Science, Technology and Research
- Oral vaccine20 Aug 2026US 2026/0240985 A1WestfäLische Wilhelms-UniversitäT MüNster
- Hemolysin antigens and vaccine embodiments for bacterial infection13 Aug 2026US 2026/0232782 A1Baylor College of Medicine
- Uropathogenic escherichia coli recombinant protein composition ls, construction, expression, and purification method therefor, and use thereof30 Jul 2026US 2026/0218156 A1Zhejiang Chinese Medical University
Most cited
By later US patents
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres118US 5,417,986 AThe United States of America as represented by the Secretary of the Army · 1995
- Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli104US 8,758,764 B2J. Craig Venter Institute, Inc. · 2014
- Avirulent microbes and uses therefor102US 5,389,368 AWashington University · 1995
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004